Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

about

Zinc oxide nanoparticles induce toxicity in CAL 27 oral cancer cell lines by activating PINK1/Parkin-mediated mitophagy.Polyphyllin I suppresses the formation of vasculogenic mimicry via Twist1/VE-cadherin pathway

P2860

Q55309086-A1568CBD-E520-4115-A6AD-0F008C74CE7B Q58763443-C3299EEC-61B5-4698-BFF6-58D59A7FB7E5

P2860

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

Item

http://www.wikidata.org/entity/Q47119535

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

@en

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

@nl

type

Item

label

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

@en

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

@nl

prefLabel

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

@en

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

@nl

P1476

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics

@en

P2093

Ahmed M E Abdalla

http://www.w3.org/2001/XMLSchema#string

Chenxi Ouyang

http://www.w3.org/2001/XMLSchema#string

Lin Xiao

http://www.w3.org/2001/XMLSchema#string

Miao Yu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Nanotechnology-mediated targeting of tumor angiogenesis

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

An orally delivered small-molecule formulation with antiangiogenic and anticancer activity

Openings between defective endothelial cells explain tumor vessel leakiness

Anti-angiogenesis and metastasis: a tumour and stromal cell alliance

Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer

Highly angiogenic peptide nanofibers

P304

533-548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/THNO.21674

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Muhammad Wajid Ullah

Guang Yang

P5008

ScienceSource

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29290825

http://www.w3.org/2001/XMLSchema#string

P921

Aillse

manufactured product

P932

5743565

http://www.w3.org/2001/XMLSchema#string

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

about

P2860

P2860

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932